Category: Non-Members
DEAPCAP, a high risk speculative asset, offers price appreciation potential, evidenced by strong short-term returns, but such...
Lasaco Assurance remains a fundamentally sound mid-tier insurer showing clear revenue and capital strength...
Adagene is a clinical-stage biopharma firm developing antibody-based immunotherapies with proprietary platforms that optimize...
Sunu Assurances exhibits strong growth, operational improvement, and regained shareholder returns. However, earnings remain...
As Oando bears stir the ship, provided are two Elliot Wave scenarios in play...
Connect Biopharma is transitioning from clinical-stage uncertainty to regulatory readiness and commercial preparation. With a...
Anebulo Pharmaceuticals is executing on a clear, high-impact strategy—developing an IV cannabis antidote for children—while...
Linkage Assurance stands out as a well-capitalized, cash-rich insurance business trading at a significant discount to book...
FTN Cocoa’s Q1 2025 report delivers encouraging signs—revenue is back, losses have significantly narrowed, and the stock is...
Our Clients Reviews
Read what our clients have to say about their experience with EWNation.
